Mark Jalkut, MD
Urology · Raleigh, NCNPI 1326054859
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,688 of the $59,513 with a category attached, or 66.7%. 44 manufacturers reported payments, led by Dendreon Pharmaceuticals LLC at 57.6% of the total. Reporting peaked in 2020 at $21,611 and has fallen 86.2% since, to $2,992 in 2025. Among urology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 558 payments — averaging $106.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$34K
- Astellas Pharma US Inc$14K
- Intuitive Surgical$4K
- Verathon Inc.$1K
- Bayer$882
- Sumitomo Pharma America, Inc.$767
- plus $4K from 38 others
Across 125 payments — averaging $3897.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dendreon Pharmaceuticals LLC$194K
- AbbVie$88K
- Sumitomo Pharma America, Inc.$77K
- Janssen Research & Development, LLC$67K
- Coloplast$30K
- Bayer$13K
- plus $18K from 3 others
What the payments were for
- Consulting fees$1,9953%
- Speaking & faculty fees$39,68867%
- Travel & lodging$2,1134%
- Food & beverage$11,18819%
- Education$4,5298%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$30,382
- XTANDI$12,327
- Da Vinci Surgical System$4,150
- NPD Clinical Study$1,250
- Nubeqa$745
- CAMCEVI$238
- AIRSEAL$125
- GEMTESA$124
- AquaBeam Robotic System$110
How this compares
$59,513 in reported general payments places this provider in the 90th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 84 | $1,206,498 |
| XtandiEnzalutamide | 88 | $1,130,174 |
| NubeqaDarolutamide | 62 | $763,591 |
| OrgovyxRelugolix | 89 | $275,923 |
| ZytigaAbiraterone Acetate | 12 | $125,876 |
| MyrbetriqMirabegron | 84 | $92,982 |
| GemtesaVibegron | 69 | $64,155 |
| Testosterone | 49 | $11,234 |
| Tamsulosin Hcl | 665 | $11,195 |
| Abiraterone Acetate | 15 | $9,315 |
| Potassium Citrate ErPotassium Citrate | 85 | $7,962 |
| Solifenacin Succinate | 91 | $4,706 |
| Testosterone Cypionate | 57 | $3,587 |
| Silodosin | 52 | $3,419 |
| Finasteride | 126 | $1,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Zytiga | $689 | $1,332,37496 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $13,612 | $1,223,156172 claims |
| BayerNubeqa | $882 | $763,59162 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $767 | $340,078158 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $37 | $9,31515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 434 urology providers in North Carolina.
Other urology in Raleigh
- John KasparRaleigh$1.1M
- Aaron LentzRaleigh$251K
- Scott BakerRaleigh$15K
- Andrew ChangRaleigh$15K
- Merry MaRaleigh$14K
- Joseph NeighborsRaleigh$12K
- Robert LippittSmithfield$11.4M
- Michael KennellyCharlotte$1.3M
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.